Frontiers in Genetics · 2022 · 19 citations · 22 references
MedicineBioinformaticsOncologyMolecular OncologyTumor MicroenvironmentTumor ProgressionCancer BiomarkersCancer Cell SignalingCancer ProgressionChemokine NetworksChemokine SignalingMolecular Classification Of TumorsCancer BioinformaticsGlioblastoma BiomarkersGlioblastoma Molecular SubtypesGlioblastoma PrognosisGlioblastoma Tumor MicroenvironmentTumor Infiltration AssessmentTumor Microenvironment BiomarkersTumor Microenvironment Effects
Background: CXCR (CXC Chemokine Receptor) is a complex of the immune-associated protein involved in tumor activation, invasion, migration, and angiogenesis through various chemical signals in the tumor microenvironment (TME). However, significant prognostic characteristics of CXCR members and their impact on the occurrence and progression of glioma have not yet been fully elucidated. Methods: In this research, we used Oncomine, TCGA, GTEx, and CGGA databases to analyze the transcription and survival data of glioma patients. Afterward, the influence of CXCR members on the TME was explored using comprehensive bioinformatics analysis. Results: The mRNA expression levels of CXCR1/2/3/4/7 were significantly up-regulated in glioma than in normal samples, whereas the mRNA expression level of CXCR5 was decreased. We then summarized the genetic alteration landscape of CXCR and identified two molecular subtypes based on CXCR expression patterns in glioma. The characteristics of CXCRs were also investigated, including the clinicopathological parameters, TME cell infiltration, and prognosis of patients with glioma. After Lasso and multivariable Cox regression, a CR-Score for predicting overall survival (OS) was constructed and the predictive performance of the signature was validated. The high-risk group was a significantly poorer prognostic group than the low-risk group as judged by the CR-Score (TCGA cohort, p < 0.001, CGGA cohort, p < 0.001). Moreover, the CR-Score was significantly correlated to the tumor-immune infiltration and cancer stem cell (CSC) index. A risk scale-based nomogram incorporating clinical factors for individual risk estimation was established thereby. Conclusion: These findings may pave the way for enhancing our understanding of CXCR modification patterns and developing better immune therapeutic approaches for glioma.
22
Robust enumeration of cell subsets from tissue expression profiles
Aaron M. Newman, Chih Long Liu, Michael R. Green et al. · Nature Methods · 2015 · 14.1K citations · Full text
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text
Life Sciences, Immunology, Oncology +17
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney, Sachet A. Shukla, Catherine J. Wu et al. · Cell · 2015 · 4.1K citations · Full text
Medicine, Immunology, Oncology +17
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Răzvan Cristescu, Robin Mogg, Mark Ayers et al. · Science · 2018 · 2.3K citations
Medicine, Immunology, Oncology +17